Project Grant R35CA294022
Award Date 9/10/25
Completion Date 8/31/32
Dollars Obligated $931K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This Project Grant award, valued at $129,058.00 and provided by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower), supports research by Dr. Anqi Wang at the University of Southern California to investigate the role of loss of Y chromosome (LOY) across the prostate cancer continuum. The research aims to evaluate LOY as a potential biomarker for prostate cancer etiology, detection, treatment, and prognosis, leveraging large prospective cohorts. The project will involve...
- The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $1,625,853 Project Grant to New York University (NYU) on December 13, 2024. The grant will support NYU's research to map and characterize the role of 3D "hubs" - regulatory DNA elements that interact with multiple loci - in the context of T-cell leukemia (T-ALL), early T-cell progenitor leukemia (ETP-ALL), and T-cell lymphoma. The project aims to better define how these 3D chromatin structures are rewired...
- This $575,051 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support the University of Arizona Cancer Center (UACC) in enhancing its NCI-funded clinical research enterprise over a 5-year period from September 1, 2025 to August 31, 2030. The key objectives are to grow the breadth of the UACC's clinical trial portfolio to better serve its diverse patient population, increase accruals to interventional treatment trials (especially NCI-sponsored...
- This $2,108,734 Project Grant was awarded on September 1, 2025 by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to The University of Texas M.D. Anderson Cancer Center to conduct a 5-year research program focused on bladder cancer. The key objectives of this research program are: 1) Developing molecular profiles of bladder cancer evolution from field effects to aggressive disease, and investigating the role of LPAR6 and CAB39L in dysregulating urothelial...
- This $3,130,492 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to improve understanding of the fundamental biological mechanisms driving the progression of Barrett's esophagus (BE) to esophageal adenocarcinoma (EA), a highly lethal cancer. The project, conducted by Arizona State University, aims to develop computational methods to analyze the spatial structure and cell type diversity in BE tissue biopsies in...
- This $150,104 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to understand the evolutionary trajectories of complex genomic rearrangements in cancer. The project aims to develop novel computational approaches, "AGAVE" and "ROSE", to characterize the timing and dynamics of focal amplifications and structural variants during tumor evolution. The research will map these evolutionary patterns across...
- The University of California, Irvine (UCI) was awarded a $2,186,372 Project Grant under the National Cancer Institute's (NCI) Cancer Biology Research program (CFDA 93.396). The 5-year grant, which began on April 1, 2025, will support a research program focused on understanding the fundamental biological mechanisms of cancer initiation and progression. The program includes three interdisciplinary research projects that will leverage mouse models to investigate the role of stochastic,...
- The University of North Carolina at Chapel Hill (UNC-CH) received a $514,582 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct research on "Targeting APOBEC3-Induced Squamous Differentiation in Bladder Cancer". The award began on March 1, 2025 and is set to conclude on February 28, 2030. The research aims to investigate the role of APOBEC3 enzymes in bladder cancer initiation and progression,...
- This $421,685 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research conducted by the University of California, San Francisco (UCSF) to investigate the "reactive" immune system in tumors and the tumor microenvironment. The study aims to discover discrete immune cell niches within the tumor that can enhance the effectiveness of cancer immunotherapies. Using innovative spatial transcriptomics, genetic tools, and cellular...
- The National Cancer Institute awarded a $1,542,555 Project Grant to Sloan-Kettering Institute For Cancer Research under the Cancer Treatment Research program (CFDA 93.395). The grant will fund research from December 2022 through November 2027 to develop more effective treatments for localized bladder cancer. Specifically, the grantee will conduct genomic analyses of bladder cancer patient cohorts to validate DNA damage response mutations as predictors of sensitivity to bacillus Calmette-Guérin...